Clinical Trial Update: Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial investigating Yttrium-90-labeled daclizumab with chemotherapy and stem cell transplant in Hodgkin lymphoma has terminated; results posted in 2017…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Disease
• Hodgkin Lymphoma

Drugs mentioned

• Daclizumab (Yttrium-90-labeled) (daclizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hodgkin Disease, Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-05-25